GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Nitrofurantoin

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The historical renal cutoff is preserved. Current product labeling and professional recommendations may use different thresholds; do not silently reconcile them.

Check source scope before reading a dose

UCSF - MACROBID: limited renal and HD evidence

Product / population
Adult oral MACROBID; lower-tract indications.
Renal method
CrCl, mL/min.
Source revision
Revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

MACROBID label and older-adult criteria use different renal thresholds

The label retains a CrCl-below-60 contraindication; the AGS 2023 older-adult criterion uses below 30. This difference does not establish safety for every patient between those values.

What to reconcile: Confirm population, lower-tract indication, duration and local policy. Document any departure from labeling; neither a source count nor this comparison selects a prescription.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

Nitrofurantoin: U.K. indexed-eGFR advice is not the U.S. CrCl label

The added historical MHRA advice differs in renal measure, cutoff and limited lower-UTI exception from the retained U.S. label and geriatric/institutional sources. It is not a new 2026 U.S. rule.

What to reconcile: Keep jurisdiction, infection site, source date and renal estimator attached to each recommendation. Do not substitute one numerical cutoff for another without clinical adjudication.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

Nitrofurantoin: label, UCSF and UK guidance remain distinct

The label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.

What to reconcile: Document jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - MACROBID: limited renal and HD evidence

Open original reference

UCSF Infectious Diseases Management Program · Adult oral MACROBID; lower-tract indications.

Renal method: CrCl, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Above CrCl 60, the institution lists 100 mg orally every 12 hours for cystitis treatment and 100 mg daily for prophylaxis. Below CrCl 60, evidence is limited and alternatives should be considered. Hemodialysis dosing data are also limited; consider alternatives. The source does not supply a validated lower-cutoff or dialysis regimen.

RDM33-professional-nitrofurantoin-C1 · Source locator: Adult non-dialysis and dialysis tables.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/nitrofurantoin-macrobid
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
c3493f812a2fd25d8bbaf99d9729c58a6655646e5ea645c8e79829b97cab1360

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=nitrofurantoin&s1=RDM33-professional-nitrofurantoin&h1=2b483d52af796bc8be20fa833d82d3316d00a70b2098f514873a1cabdc0fc5c9